Longevity Lab ReportBeta
← All supplements

Supplement

Tesamorelin

A prescription growth-hormone peptide for HIV belly fat, used off-label for aging.

Tesamorelin is a synthetic growth-hormone-releasing-hormone analog that prompts the pituitary to release growth hormone, which selectively burns deep visceral fat. We grade Tesamorelin B on evidence and C- for worth-it at about $8,000-11,000 per month.

B

Evidence

C-

Worth it

Typical cost: $8,000-11,000/month

What it does

Tesamorelin is a synthetic growth-hormone-releasing-hormone analog that prompts the pituitary to release growth hormone, which selectively burns deep visceral fat. It is an FDA-approved PRESCRIPTION drug (brand Egrifta, approved 2010) for HIV-associated lipodystrophy only; any longevity or general fat-loss use is off-label and not FDA-approved.

What the research says

  • Reduces visceral fat by about 15-18% over 26 weeks in HIV lipodystrophy patients

    Evidence: strong. Two Phase III trials (roughly 800 patients total) showed significant visceral fat reduction versus placebo, the basis for FDA approval.

  • Improved executive function and memory in older adults

    Evidence: weak. A single small Phase 2 trial (about 150 older adults, 20 weeks) reported cognitive gains with IGF-1 roughly doubling; not replicated.

  • Reduces liver fat

    Evidence: weak. Exploratory studies in HIV patients suggest liver-fat benefits; no large confirmatory trials.

The strongest peptide-level evidence in this batch, but it comes from a specific patient population (HIV-associated lipodystrophy) and a narrow indication. Off-label longevity, cognition, and general fat-loss claims have no dedicated trials; stopping the drug lets the fat return.

Is it worth it?

C-

The labeled prescription product is extraordinarily expensive and insurance covers only the approved indication. Gray-market research vials are unregulated in dose and purity. Effects require ongoing use, so the cost-per-benefit math for off-label longevity use is poor.

Typical cost

$8,000-11,000/month

Common form, not a brand recommendation

Dosage contextestablished

FDA-labeled dose is 2 mg/day subcutaneously for HIV lipodystrophy. No established dose exists for off-label longevity use; community protocols of 1-2 mg/day are unvalidated.

Safety notes

PRESCRIPTION DRUG: requires a prescription and monitoring of blood sugar and IGF-1. Known risks include injection-site reactions, joint pain and swelling, carpal-tunnel symptoms, fluid retention, and raised blood sugar (contraindicated with active malignancy and in pregnancy). Never use research-market vials as medicine: they have no verified dose, purity, or sterility.

Longevity Lab Report

Tesamorelin news, graded when it happens.

New studies, dose debates, and expert shifts on tesamorelin, in one email a week. Free.

Changelog

Last updated 2026-10-15

  • 2026-10-15|Batch 2 DRAFT entry.
  • 2026-10-15|Flagged as prescription drug; excluded from builder recommendations.